TZ9

• CAT Number: I000078
• CAS Number: 1002789-86-7
• Molecular Formula: C17H14N6O4
• Molecular Weight: 366.30
• Purity: ≥95%
• Synonyms: (4-amino-6-(phenylamino)-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate
• Target: Apoptosis
• Solubility: DMSO: ≥ 40 mg/mL
• Storage: Store at -20°C
• IC50: 6 uM
• IUPAC Name: (4-amino-6-anilino-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate
• InChI: InChI=1S/C17H14N6O4/c18-16-20-14(21-17(22-16)19-12-4-2-1-3-5-12)10-27-15(24)11-6-8-13(9-7-11)23(25)26/h1-9H,10H2,(H3,18,19,20,21,22)
• InChIKey: RRRDZFQRNJTKHL-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)NC2=NC(=NC(=N2)N)COC(=O)C3=CC=C(C=C3)[N+](=O)[O-]

TZ9（Cat No.:I000078）is a novel small-molecule compound known for its selective inhibition of cyclin-dependent kinase 9 (CDK9), a key regulator in transcriptional elongation and cell cycle progression. By targeting CDK9, TZ9 disrupts the transcription of genes critical for cancer cell survival, particularly in cancers dependent on continuous transcription of oncogenes. Its selective action on CDK9 reduces unintended effects on other kinases, enhancing its safety and efficacy profile. TZ9 is valuable in preclinical cancer research and drug development, particularly for studying transcriptional regulation in cancer and exploring targeted cancer therapies.

Reference

[1]. Sanders MA, et al. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. Mol Cancer Ther. 2013 Apr;12(4):373-83.